US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

Data Compilation
#PharmaFlow

Pipeline Prospector April 2025: Merck KGaA buys SpringWorks for US$ 3.9 bn; Swiss giants lead pharma migration to US soil

Stock Recap
#PipelineProspector

Aciclovirum [Latin]

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

127 API Suppliers, 33 USDMF, 19 CEP/COS, 8 JDMF, 13 EU WC, 36 KDMF, 26 NDC API, 50 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

6 Intermediate Suppliers

6 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

400 FDF Dossiers, 97 FDA Orange Book, 122 Europe, 17 Canada, 18 Australia, 30 South Africa, 116 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 200MG/5ML, TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 6 SPI Pharma, 11 DKSH, 6 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 36 BASF, 3 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 22 Kerry, 1 Kima Chemical, 3 Lonza Capsugel, 14 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 3 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 Silverline Chemicals, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

67 Fillers, Diluents & Binders, 39 Disintegrants & Superdisintegrants, 37 Thickeners and Stabilizers, 29 Direct Compression, 27 Granulation, 25 Topical, 23 Coating Systems & Additives, 22 Solubilizers, 18 Film Formers & Plasticizers, 16 Controlled & Modified Release, 16 Lubricants & Glidants, 12 Parenteral, 12 Taste Masking, 11 Chewable & Orodispersible Aids, 11 Co-Processed Excipients, 8 Empty Capsules, 7 Emulsifying Agents, 6 Rheology Modifiers, 3 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin, 1 API Stability Enhancers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 49 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 113 Regulatory FDF Prices

MARKET PLACE

41 APIs, 23 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 1 US Exclusivities, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 12 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
19/05/2025	Apex Healthcare	India	M/s. Apex Healthcare Limited	WC-0409	Aciclovir BP/EP/USP	2024-03-01	2026-12-31	4710, 4711, 4707-A/8, 4707-A/9, GIDC, Industrial Estate, Ankleshwar, Dist.Bharuch-393002, Gujarat,
04/04/2025	Apex Healthcare	India	M/s Apex Healthcare Linited	WC-0409	Aciclovir (BP/EP/USP)	2024-03-01	2026-12-31	4710, 4711, 470748, 470749, GIDC,Industrial Estate, Ankleshwar, Dist.Bharuch-393002, Gujarat, India

Aciclovirum [Latin]

Aciclovirum [Latin]

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

127 API Suppliers

33 USDMF

19 CEP/COS

8 JDMF

13 EU WC

36 KDMF

26 NDC API

50 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

7 Drugs in Development

INTERMEDIATES

6 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

400 FDF Dossiers

97 FDA Orange Book

122 Europe

17 Canada

18 Australia

30 South Africa

116 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 200MG/5ML

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Rochem International Inc

6 SPI Pharma

11 DKSH

6 Faran Shimi Pharmaceutical

5 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

4 ACG Worldwide

5 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

36 BASF

3 Corel Pharma Chem

6 DFE Pharma

2 Finar

9 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

22 Kerry

1 Kima Chemical

3 Lonza Capsugel

14 Microlex e.U

2 Nanjing Bold Chemical

2 Nomisma Healthcare

2 Novo Excipients

4 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

3 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

4 Silverline Chemicals

1 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

4 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

67 Fillers, Diluents & Binders

CAPSULE;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 800MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons